Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists

Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists

Abstract Insulin analogs have been developed to treat diabetes with focus primarily on improving the time action profile without affecting ligand-receptor interaction or functional selectivity. As a result, inherent liabilities (e.g. hypoglycemia) of injectable insulin continue to limit the true the...

Full description

Bibliographic Details
Main Authors: Margaret Wu, Ester Carballo-Jane, Haihong Zhou, Peter Zafian, Ge Dai, Mindy Liu, Julie Lao, Terri Kelly, Dan Shao, Judith Gorski, Dmitri Pissarnitski, Ahmet Kekec, Ying Chen, Stephen F. Previs, Giovanna Scapin, Yacob Gomez-Llorente, Scott A. Hollingsworth, Lin Yan, Danqing Feng, Pei Huo, Geoffrey Walford, Mark D. Erion, David E. Kelley, Songnian Lin, James Mu
Format: Article
Language:English
Published: Nature Portfolio 2022-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-28561-9

Internet

https://doi.org/10.1038/s41467-022-28561-9

Similar Items